Advertisement
Screener

Aditxt, Inc. (ADTX) Proceeds from Notes Payable

2.8 / 5 stars · 68/120 Roast Me

Aditxt, Inc. Proceeds from Notes Payable

Aditxt, Inc. (ADTX) reported Proceeds from Notes Payable of $451.97 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-19.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromNotesPayable · last filed 2025-03-31

  • Aditxt, Inc. proceeds from notes payable for the quarter ending 2024-06-30 was $0.00.
  • Aditxt, Inc. proceeds from notes payable for the quarter ending 2024-03-31 was $451.97K.
  • Aditxt, Inc. proceeds from notes payable for the quarter ending 2022-09-30 was $2.59M.
  • Aditxt, Inc. proceeds from notes payable for the quarter ending 2021-12-31 was $0.00.
  • Aditxt, Inc. proceeds from notes payable for fiscal 2021 was $5.00M, a 1233.33% increase from fiscal 2020.
  • Aditxt, Inc. proceeds from notes payable for fiscal 2020 was $375.00K, a 650.00% increase from fiscal 2019.
  • Aditxt, Inc. proceeds from notes payable for fiscal 2019 was $50.00K.
Period endProceeds from Notes PayableProceeds from Notes Payable 3 monthProceeds from Notes Payable 6 monthProceeds from Notes Payable 9 monthProceeds from Notes Payable 12 month
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19
$451.97K
10-Q · filed 2024-08-19
2024-03-31$451.97K
10-Q · filed 2024-05-20
2023-10-05$3.00M
10-K · filed 2025-03-31
2022-09-30$2.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$3.14M
10-Q · filed 2022-11-14
2022-06-30$550.00K
10-Q · filed 2022-08-15
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$0.00
derived: sum of 2 quarters · filed 2022-11-14
$0.00
derived: sum of 3 quarters · filed 2022-11-14
$5.00M
10-K · filed 2022-03-31
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$0.00
derived: sum of 2 quarters · filed 2022-11-14
$5.00M
10-Q · filed 2022-11-14
$5.00M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$5.00M
10-Q · filed 2022-08-15
$5.00M
derived: sum of 3 quarters · filed 2022-08-15
$5.00M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$5.00M
10-Q · filed 2022-05-16
$5.00M
derived: sum of 2 quarters · filed 2022-05-16
$5.00M
derived: sum of 3 quarters · filed 2022-05-16
$5.04M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$0.00
derived: sum of 2 quarters · filed 2022-03-31
$40.00K
derived: sum of 3 quarters · filed 2022-03-31
$375.00K
10-K · filed 2022-03-31
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$40.00K
derived: sum of 2 quarters · filed 2021-11-15
$375.00K
10-Q · filed 2021-11-15
2020-06-30$40.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$375.00K
10-Q · filed 2021-08-12
2020-03-31$335.00K
10-Q · filed 2021-05-12
2019-12-31$50.00K
10-K · filed 2021-03-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Rafael Holdings, Inc. (RFL)United States$0.000B-0.00
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B